NAD+ research: the mechanism, the precursor trials, and the gaps

The short version

Here is the NAD+ research in plain terms. NAD+ (the cell's fuel-handling helper molecule) is both an energy carrier and a substrate that maintenance enzymes burn up. As we age, an enzyme called CD38 rises and eats into the NAD+ supply ^[2]. The repair strategy people test is to feed the system a precursor (a building block the body turns into NAD+) — usually NMN or NR. Randomized trials show these reliably raise blood NAD+ ^[4][3][7]. A few trials show functional changes like better muscle insulin sensitivity ^[1]; a 2025 review says the human payoff for hard health outcomes is still unproven ^[15]. Below, every claim is stamped to its study.

The mechanism: NAD+ as carrier and as consumed substrate

NAD+ does two jobs. First, it cycles between its oxidized form (NAD+) and reduced form (NADH) to shuttle electrons through glycolysis, the TCA cycle, and the mitochondrial electron transport chain — the machinery that makes ATP ^[5]. Second, it is a consumed substrate: three enzyme families cut NAD+ apart to do their work ^[5].

Those families are the sirtuins (SIRT1-7, NAD+-dependent enzymes that regulate metabolism, stress resistance, and DNA repair), PARP1 (a DNA-repair enzyme that burns large amounts of NAD+ when DNA is damaged), and CD38/CD157 (NAD-consuming enzymes on cell surfaces that rise with age and inflammation) ^[5]. Because these enzymes compete for the same pool, NAD+ is a shared, limited resource.

Cells replenish it mainly through the salvage pathway, recycling nicotinamide back into NAD+ via the rate-limiting enzyme NAMPT ^[5]. NR enters through a separate route, converted to NMN by the NRK kinases, then to NAD+ ^[6]. This is why precursors work: they top up the salvage and NRK routes.

Why tissue NAD+ falls with age

Tissue NAD+ declines with age across model organisms and, in a limited number of studies, humans ^[5]. A central driver is CD38. In mice, CD38 is the principal NAD+-consuming enzyme whose activity rises with age, and CD38-knockout mice are protected against the age-related NAD+ fall, preserving SIRT3 activity and mitochondrial function ^[2]. As CD38 climbs, it draws down the pool faster than synthesis replaces it.

That decline is the rationale behind precursor supplementation: if the pool is shrinking, feeding it more raw material may hold levels up ^[5]. The logic is sound and the blood-NAD+ data support the first step. The unsettled question is whether higher blood NAD+ restores the downstream functions that age-related decline impairs ^[15].

Nicotinamide riboside (NR): the most-studied oral NAD+ precursor

Nicotinamide riboside (NR) is the most clinically studied oral NAD+ precursor. It is uniquely and orally bioavailable: in humans, single doses of 100, 300, and 1000 mg dose-dependently raised whole-blood NAD+, with a 1000 mg dose raising NAD+ roughly 2.7-fold over 24 hours and lifting the internal biomarker NAAD more than 25-fold ^[6]. Over eight weeks, NR at 100/300/1000 mg/day raised whole-blood NAD+ by 22%/51%/142% in healthy overweight adults, with no flushing and no adverse-event difference from placebo at any dose ^[4].

Chronic dosing holds the rise: NR at 1000 mg/day for six weeks raised whole-blood NAD+ about 60% in middle-aged and older adults, was well tolerated, and showed a trend toward reduced aortic stiffness and lower systolic blood pressure ^[7]. Pharmacokinetic profiling established NAAD as a robust marker of pathway flux, with no serious adverse events across doses ^[10]. NR is the clearest case of an oral precursor reliably and safely raising the NAD+ pool.

Nicotinamide mononucleotide (NMN): one step from NAD+

Nicotinamide mononucleotide (NMN) sits one biochemical step from NAD+. Single oral doses of 100, 250, and 500 mg in healthy men were safely absorbed and raised serum NMN metabolites, with no clinically significant changes in heart rate, blood pressure, oxygen saturation, sleep, or laboratory parameters ^[8]. A proposed absorption route is the intestinal transporter Slc12a8, reported in mice to carry NMN directly, though other groups have debated the finding ^[9].

The functional signal comes from a 2021 trial: 10 weeks of NMN at 250 mg/day improved muscle insulin sensitivity in prediabetic, postmenopausal women, without changing body composition or HbA1c ^[1]. A 2023 multicenter, double-blind RCT tested 300, 600, and 900 mg/day for 60 days, found blood NAD+ rose significantly across all groups versus placebo, identified 600 mg/day as the optimal dose, reported improved walking distance, and recorded no safety issues at any dose ^[3]. NMN is a precursor — these are not studies of NAD+ taken directly.

NAD supplement framing: precursors, not the coenzyme itself

A NAD supplement on the market is, in nearly every case, a precursor product — NMN, NR, or niacin/nicotinamide — because oral NAD+ is poorly absorbed intact ^[6][8]. The published efficacy evidence is precursor evidence. This digest keeps the NAD supplement category and the NAD+ coenzyme distinct: when a study raised blood NAD+, it did so by delivering a precursor, and the figures here are always attributed to the precursor and dose that produced them ^[4][3].

Beyond blood NAD+: model-organism findings

Most of the strongest anti-aging and disease data come from animals, and may not extrapolate to humans ^[15]. In glaucoma-prone mice, retinal NAD+ fell with age, and oral nicotinamide was protective — 93% of eyes did not develop glaucoma at the highest dose tested ^[14]. In a noise-exposure model, NR given before exposure preserved cochlear ribbon synapses and aided hearing recovery ^[12]. A topical-nicotinamide review reported reduced skin-aging progression and hyperpigmentation in clinical trials, attributed to NAD+ replenishment in skin ^[16].

NAD+ also has a dual role in cancer biology. In BRAF-inhibitor-resistant melanoma, resistant cells upregulated the NAD+ biosynthetic enzyme NAMPT, and a NAMPT inhibitor depleted NAD+ and ATP and improved survival in xenograft-bearing mice ^[13]. This is a context-dependent finding: it identifies NAD+ biosynthesis as a vulnerability some tumors exploit, which is why a theoretical concern exists that boosting NAD+ could support proliferating cells in cancer populations ^[15].

Tolerability and adverse events in the studies

Across the cited oral-precursor trials, NMN and NR were generally well tolerated, with no serious adverse events even at high doses ^[4][7][8]. The Conze 2019 NR trial reported no flushing and no adverse-event difference from placebo at up to 1000 mg/day ^[4]. The Martens 2018 chronic NR trial at 1000 mg/day for six weeks recorded good tolerability ^[7]. Single-dose NMN up to 500 mg produced no clinically significant vital-sign or laboratory changes ^[8].

The safety picture differs sharply for the injectable route. IV NAD+ infusions can cause chest and abdominal discomfort, flushing, and nausea when run too fast, and a compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin. These are not equivalent: the oral-precursor tolerability record is reassuring within the trials; the compounded-injectable record carries documented quality risk. NAD+ side effects are therefore route-dependent, and the frequently asked questions about NAD+ break the distinction down further.